Invitrogen's Q1 Revenues Climb 13.5 Percent as Profit Nearly Doubles | GenomeWeb
This article has been updated to include comments from a conference call and a stock quote.
 
NEW YORK (GenomeWeb News) – Invitrogen reported after the close of the market today that its first-quarter revenues rose 13.5 percent and its profit nearly doubled.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.